However, a recent clinical study testing ceftriaxone, an FDA-approved β-lactam antibiotic that can transcriptionally promote EAAT2 expression (Lee et al., 2008; Rothstein et al., 2005), in ALS patients concluded that this drug treatment had no therapeutic effect (Cudkowicz et al., 2014). This evidence concerns the gene SLC1A2 and amyotrophic lateral sclerosis.